India Pharma Outlook Team | Tuesday, 27 October 2026
TROP2 ADC development has reached a significant clinical milestone after Merck’s experimental cancer drug sacituzumab tirumotecan (sac-TMT) extended survival in patients with advanced or recurrent endometrial cancer.
Results from the Phase 3 TroFuse-005 trial showed that the treatment reduced the risk of death by 32 percent compared with chemotherapy.
The data led the US FDA to take Merck’s application under priority review, with a regulatory action to be expected by June 2027.
Beyond the survival benefit, the findings highlight a persistent treatment gap for patients whose cancer progresses after platinum-based chemotherapy and immunotherapy, raising questions about how targeted therapies could reshape later-line cancer care.
The TroFuse-005 trial enrolled 776 patients with advanced or recurrent endometrial cancer whose disease had progressed following platinum-based chemotherapy and anti-PD-1 or anti-PD-L1 immunotherapy.
Participants received either sac-TMT or physician-selected chemotherapy with doxorubicin or paclitaxel. Median overall survival reached 19 months with sac-TMT, compared with 12.1 months in the chemotherapy group.
The treatment also reduced the risk of disease progression or death by 41 percent, extending median progression-free survival to 7.2 months from 3.9 months.
Tumour shrinkage was reported in approximately 35 percent of patients receiving sac-TMT, compared with 17 percent among the chemotherapy group.
These results position the TROP2 ADC as a potential option for patients with limited treatment choices after standard therapies stop controlling their disease. Sac-TMT uses an antibody to target the TROP2 protein and deliver a cancer-killing payload to the cells.
The findings could also influence the development of endometrial cancer treatment strategies, although the drug remains investigational for this indication in the US.
Also Read: India's Role in Shaping the Future of Oncology and Immunology
The survival improvement must be considered alongside the treatment’s safety profile. Severe treatment-related adverse events occurred in approximately 54 percent of patients receiving sac-TMT, compared with 41 percent in the chemotherapy group.
Around 3 percent of patients in the sac-TMT arm discontinued treatment because of treatment-related side effects.
For oncologists assessing a new endometrial cancer treatment, the balance between prolonged survival, disease control and tolerability will be important.
The wider development of TROP2-targeted therapy reflects pharmaceutical companies’ efforts to improve the delivery of cancer medicines.
Antibody-drug conjugates combine target recognition with a potent drug payload, but their clinical value depends on both efficacy and manageable toxicity.
The FDA’s priority review gives Merck an accelerated regulatory timetable, with an action date expected in June 2027. Merck is developing sac-TMT in collaboration with China-based Kelun-Biotech, which discovered the drug.
The partnership illustrates how licensing arrangements between biotechnology companies and global pharmaceutical manufacturers can advance investigational medicines into large international trials.
For pharmaceutical developers, the trial highlights the importance of identifying patients with substantial unmet needs and demonstrating meaningful clinical benefits against established treatment options.
Whether sac-TMT becomes a new standard treatment will depend on regulatory review, subsequent evidence, and its eventual role alongside other therapies.
.jpg)
